Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

There is an urgent need for an improved vaccine against tuberculosis. Heterologous prime-boost immunization regimes induce higher levels of cellular immunity than homologous boosting with the same vaccine. Using BCG as the priming immunization in such a regime allows for the retention of the beneficial protective effects of BCG against disseminated disease in childhood. Recombinant poxviruses are powerful boosting agents, for both CD4+ and CD8+ T cells. Here we review the preclinical data from a BCG prime-recombinant modified vaccinia virus Ankara expressing antigen 85A (MVA85A) boost strategy. MVA85A is now in clinical trials in the UK and Africa and the design of these trials, including the ethical and regulatory issues are discussed.

Original publication

DOI

10.1016/j.tube.2004.09.015

Type

Journal article

Journal

Tuberculosis (Edinb)

Publication Date

01/2005

Volume

85

Pages

47 - 52

Keywords

BCG Vaccine, Clinical Trials as Topic, Humans, Immunity, Cellular, Mycobacterium tuberculosis, T-Lymphocytes, Tuberculosis, Tuberculosis Vaccines, Vaccines, Subunit, Vaccinia virus